Methoxy polyethylene glycol-epoetin beta - Roche

Drug Profile

Methoxy polyethylene glycol-epoetin beta - Roche

Alternative Names: C.E.R.A.; CERA; Continuous erythropoietin receptor activator; Mircera; R-744; RG744; RO 503821; RO-0503821

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Chemotherapy-induced anaemia

Most Recent Events

  • 27 Sep 2017 Vifor Pharma expands license agreement with Roche for commercialisation of Methoxy polyethylene glycol-epoetin beta in USA
  • 15 Dec 2016 Biomarkers information updated
  • 28 May 2015 Methoxy polyethylene glycol-epoetin beta licensed to Galenica Group in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top